- Conditions
- Cervical Cancer, Cervix
- Interventions
- Tissue Repository
- Genetic
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,727
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
- Interventions
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Procedure
- Lead sponsor
- Elephas
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
- Conditions
- Cancer
- Interventions
- monoclonal antibody RAV12
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Dasatinib, Laboratory Biomarker Analysis, Paclitaxel
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Uterine Fibroids
- Interventions
- Embozene® Microspheres, Embosphere®
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Albany, New York • New Hyde Park, New York
- Conditions
- Breast Cancer, Cervical Cancer
- Interventions
- Health literacy, health message
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 560 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Ellicott City, Maryland
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
- Interventions
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
- Interventions
- Ca-125, screening questionnaire administration, Surgery
- Other · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 6,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2040
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma
- Interventions
- therapeutic angiotensin-(1-7), laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
- Interventions
- SNS-101 (anti-VISTA), Cemiplimab
- Drug
- Lead sponsor
- Sensei Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
- Interventions
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Procedure
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 22
- States / cities
- Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
- Conditions
- Cervical Cancer
- Interventions
- iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
- Drug · Procedure · Radiation
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • New York, New York
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, topotecan hydrochloride, brachytherapy, radiation therapy
- Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Endometrial Cancer
- Interventions
- Ixabepilone, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Englewood, Colorado • New Haven, Connecticut + 25 more
- Conditions
- Postoperative Pain, Fibroid Uterus
- Interventions
- Bupivacain, Saline
- Drug
- Lead sponsor
- Joseph Findley MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Beachwood, Ohio
- Conditions
- Uterine Fibroids, Vaginal Bleeding
- Interventions
- Office hysteroscopy, Endometrial biopsy
- Procedure
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cervical Cancer
- Interventions
- Demographic Form and Semi-Structured Interview Guide
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- High Grade Cervical Intraepithelial Neoplasia
- Interventions
- DySIS
- Device
- Lead sponsor
- DySIS Medical Inc.
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 7,555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 46
- States / cities
- Scottsdale, Arizona • Gainesville, Florida • Jacksonville, Florida + 39 more
- Conditions
- Ovarian Cancer, Sarcoma
- Interventions
- dolastatin 10
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Rochester, Minnesota • Columbus, Ohio + 1 more
- Conditions
- Solid Tumor, Colorectal Cancer, Endometrial Cancer
- Interventions
- DS-7423
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • New York, New York • Nashville, Tennessee
- Conditions
- Cervical Cancer
- Interventions
- Flocked swab paired with Roche Cobas 4800
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Endometrial Cancer
- Interventions
- Tailored Feedback Messages
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, vinorelbine tartrate
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 9
- States / cities
- Orange, California • Honolulu, Hawaii • Baltimore, Maryland + 6 more